Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ensysce Biosciences Inc

ENSC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.40

▲ +14.75%

Market Cap $7.78M · Vol 495.07K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$7.78M

Micro Cap

Div Yield

N/A

EPS Growth

+68.09%

YoY

RSI (14)

62.27

Momentum

Beta

1.06

vs Market

52W High

$2.74

85.41% below

52W Low

$0.24

69.45% above

Volume

495.07K

Avg 923.46K

P/B

1.31

Price-to-book

ROE

N/A

Return on equity

Free Float

99.35%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Ensysce Biosciences Inc (ENSC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ENSC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-23.13%

+36.72%

+44.26%

-8.07%

YTD

-56.53%

-80.59%

-98.63%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$5.07M
Net Income	$-10,176,190.00
Revenue Growth (YoY)	-15.10%
Gross Margin	100.00%
Operating Margin	-202.12%
Net Profit Margin	-200.85%
ROE	N/A
ROA · ROIC	-155.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.46
P/B	1.31
P/FCF	N/A
EPS Growth	+68.09%
Outstanding Shares	19.46M

Technical Indicators

50-Day SMA	$0.30
200-Day SMA	$0.73
RSI (14)	62.27
Beta	1.06
52-Week High	$2.74
52-Week Low	$0.24

Volume Today	495.07K
Avg Daily Volume (30D)	923.46K
Relative Volume	0.54x
Volatility (10D)	276.73
Volatility (30D)	170.33
Free Float	99.35%

Analyst Consensus

N/A

Current Price $0.40

Mean Target $8.25

52W Low$0.24 52W High$2.74

Current

Target

$0.24 $2.74

Current Analyst target

+1,963.02% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00JFF4183

ISINUS2936025046

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.